VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report)'s stock had its "outperform" rating reiterated by equities research analysts at William Blair in a report released on Wednesday,RTT News reports.

VistaGen Therapeutics Trading Down 13.4%

Shares of VTGN traded down $0.32 during mid-day trading on Wednesday, hitting $2.06. The company's stock had a trading volume of 415,107 shares, compared to its average volume of 173,002. The firm has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $2.58. The firm has a market capitalization of $59.45 million, a P/E ratio of -1.24 and a beta of 0.70. VistaGen Therapeutics has a 1-year low of $1.90 and a 1-year high of $4.21.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its quarterly earnings data on Tuesday, June 17th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.10. VistaGen Therapeutics had a negative return on equity of 55.31% and a negative net margin of 6,777.08%. The firm had revenue of ($0.01) million during the quarter, compared to analysts' expectations of $0.18 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. As a group, sell-side analysts predict that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several large investors have recently added to or reduced their stakes in VTGN. Cubist Systematic Strategies LLC purchased a new position in VistaGen Therapeutics during the first quarter worth about $25,000. Two Sigma Advisers LP purchased a new position in shares of VistaGen Therapeutics in the 4th quarter worth about $35,000. Man Group plc purchased a new position in shares of VistaGen Therapeutics in the 4th quarter worth about $54,000. Bank of America Corp DE raised its holdings in shares of VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock worth $62,000 after purchasing an additional 19,331 shares during the period. Finally, Boothbay Fund Management LLC purchased a new position in shares of VistaGen Therapeutics in the 4th quarter worth about $66,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.